Regional Chapter Annual Report - 2015

Chapter Region
Russia St. Petersburg Europe

President
Alexey Kolbin, MD, PhD, Doctor of Science Head of the department of clinical pharmacology and evidence-based medicine First Pavlov State Medical University of St. Peterburg; Professor of Department of Pharmacology, Faculty of Medicine St. Petersburg State University; alex.kolbin@mail.ru

President-Elect
Edwin Zvartau, MD, PhD, Doctor of Science, Professor, Head of the Department of Pharmacology; zvartau@spb-gmu.ru

Past President
Alexey Kurilev, MD, Department of clinical pharmacology and evidence-based medicine First Pavlov State Medical University of St. Peterburg; alexey-kurilev@yandex.ru

Secretary

# Members
15

I. The following articles have been published in Russian and International journals about pharmacoeconomical and health technology assessment researches:
9. Adverse effects of systemic interferons. Safety

Describe your Chapter's accomplishments for 2015 with regard to Scientific and Educational activities.
Regional Chapter Annual Report - 2015

44. Comparative clinicoeconomic analysis of Iodantipirin for an emergency prevention of tick-borne encephalitis. Qualitative Clinical Practice, №1, 2015, p. 44-52. Ashihmin Y.I., Belousov D.Y., Afanasyeva
for treatment of moderate and severe forms of psoriasis
Regional Chapter Annual Report - 2015


16/11/2015 Moscow  21. 3rd Transregional Scientific and Practical Symposium "HIV Medicine and Pharmacoeconomics" Russian Academy of Science (RAS), Health Committee (HC), Pavlov First Saint Petersburg State Medical University, Institute of Experimental Medicine of North-Western Section of RAS, St Petersburg Centre for Prevention and Control of HIV and Infectious Diseases, Baltic Medical Educational Centre - Chronic Hepatitis C: Pharmacoeconomic Aspects - Maintenance, Financing and Results of HIV Prevention Programs for Maternity and 19.02.15 St Petersburg  22. Conference "The Wrap-Up of 2014. The Difficult 2015". Pharmaceutical Association St Petersburg and The North West The Analysis of A New List of Vital and Most Important Drugs 2015 27.02.15 St Petersburg 23. XXXVII Concluding Scientific and Practical Conference "Current Issues in Children's Infectious Diseases 2015" HC, Association fo Neurologists, Research Institute for Children's Infections, St Petersburg State Pediatric Medical Institute, Association of Infectiologists of St Petersburg and Leningrad Oblast Cost effectiveness of Teratment and Prevention of Infectious Diseases 10.03.15 St Petersburg  24. School "Prostate Cancer" Russian Society of Clinical Oncology Pharmacoeconomic Aspects of Abiraterone Therapy of Metastatic Prostate Cancer 10.04.15 St Petersburg  25. Round Table "Medical Care and Drug Provision for Elderly Patients" Health Committee of the State Duma of the Federal Assembly Pharmacoeconomic Aspects of Treating Elderly Patients 08.06.15 Moscow  26. IV All-Russian Interregional Congress "Baltic Medical Forum" Autonomic nonprofit organization "Consultive and Information Centre "Medical Science and Technologies” Pharmacoeconomic Aspects of Prevention, Diagnosis and Therapy of Socially Signifcant Diseases 24.06.15 St Petersburg  27. Scientific and Practical Conference "Rational Pharmacotherapy in Contemporary Endocrinology” Health Committee of St Petersburg, Professional Association of Clinical Pharmacologists of St Petersburg Pharmacoeconomic Aspects of SGLT2 Inhibitor Therapy for Type 2 Diabetes 25.06.15 St Petersburg  28. Scientific and Practical Conference "Uncomplicated Urinary Tract Infections. Unifying Standards and Clinical Practice” Health Committee Therapy for Acute Cystitis. Analysis of Evidence and Costs of Treatment 25.06.15 St Petersburg  29. Round Table “Lists of Drugs. Will Innovative Drugs Be Available for Patients?” Media Center of "Rossiyskaya Gazeta" Pharmacoeconomic Aspects of Innovative Drug Use 25.08.15 Moscow  30. International Congress "HIV Infections. Diagnostic, Therapeutic, Preventive, and Prognostic Issues” (VII Vinogradov Readings) RAS, HC,
Regional Chapter Annual Report - 2015

Pavlov First Saint Petersburg State Medical University, Institute of Experimental Medicine of North-Western Section of RAS, St Petersburg Centre for Prevention and Control of HIV and Infectious Diseases, Baltic Medical Educational Centre Pharmacoeconomic Aspects of Effective HAART Schemes 14.10.15 St Petersburg  
32. Expert Council “HPV Vaccination Program in St Petersburg. Results of Implementation and Perspectives” HC Pharmacoeconomic Aspects of HPV Vaccination in the RF 29.10.15 St Petersburg  
III. Oral Presentations at the ISPOR International and European Meeting:  
IV. Poster Presentations at the ISPOR International and European Meeting:  
3. ISPOR. 18TH ANNUAL EUROPEAN CONGRESS ISPOR. RESEARCH ABSTRACTS. Value in health. 2015:18(7); A443 PHARMACOECONOMIC ANALYSIS OF THE USE OF EVEROLIMUS COMPARED TO AXITINIB IN SECOND LINE THERAPY OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA. Kolbin A, Frolov M, Kurylev A, Balykina Y, Proskurin M  
6. ISPOR. 18TH ANNUAL EUROPEAN CONGRESS ISPOR 18th Annual European Congress, November 7 - 11, 2015, Milan, Italy. Poster presentation. Abstract presentation. Budget impact
Describe your Chapter's accomplishments for 2015 with regard to Policy-related activities.

1. Modeling the inclusion of drugs in the Russian government's reimbursement lists. This research we presented to the Federal Ministry of Health.

2. We are conducting pharmacoepidemiology research for State insurance Fund about using antibiotics in state hospitals in SPb.

Describe your Chapter's accomplishments for 2015 with regard to Chapter meetings or conferences.


2. Meeting about HTA into St. Petersburg International Innovation Forum 2015, 9/10/2015

Describe your Chapter's accomplishments for 2015 with regard to membership engagement.

Is your Chapter affiliated with any institutions, universities, government or associations (other than ISPOR)? If yes, please list and describe the nature of these affiliations(s).

No

Does your Chapter collect membership dues or fees from individuals for local Chapter membership? If yes, how much are the dues?

No

How many ISPOR International members (paying dues to ISPOR Headquarters) does your Chapter have? Provide an estimate if you do not have an exact count.

4

Does your Chapter have any agreements or sponsorship arrangements with any for-profit companies, governments, health authorities or associations? If yes, please describe.

No

Does your Chapter employ paid administrative or management staff (Association Management Company, contracted staff)?

No

Other than the page for your Chapter on the ISPOR website, does your Chapter maintain a website?

Yes
When did your Chapter last update the ISPOR Chapter Constitution?

In the last 3 years.

Has your Chapter (as a group, not as individual members) submitted formal comments or responses to any government or health authority in 2014 or 2015? If yes, what was the topic or issue?

Yes

Modeling the inclusion of drugs in the Russian government's reimbursement lists. This research we presented to the Federal Ministry of Health.

Does your Chapter (as a group, not as individual members) interact in some way with the HTA or other official guidelines in your country? If yes, please name guideline(s) and describe.

Yes

Centre of Expertise and quality control of medical products. Moscow.

Does your Chapter have any committees or special interest groups? Please indicate and briefly describe.

Yes

1. Mathematical model for predicting the development of bacterial resistance

Academia %
Government/HTA Agency %
Industry %
Consulting %
Clinicians %
Student %
Other %

20
10

What benefits does your Chapter offer to its members?

International communication with colleagues from other countries

1. Modeling the inclusion of drugs in the Russian government's reimbursement lists. This research we presented to the Federal Ministry of Health. 2. We are conducting pharmacoepidemiology research for State insurance Fund about using antibiotics in state hospitals in SPb.

What are the most significant achievements of your Chapter in 2015?

taking part in the international conference due to the problems with funding

What are the greatest challenges facing your Chapter?
How does your Chapter fulfill ISPOR’s mission to promote health economics and outcomes research excellence to improve decision making for health globally? Describe how it supports the development and promotion of the discipline of health economics and outcomes research in your region.

How can the ISPOR organization as a whole (Staff, Board, Consortia, Networks, etc.) better support your Chapter?

We have own educational courses. 1. Main issues of health technology assessment (technology used in health care. The schedule was 6 days a week during 1 month, totally 144 hours. May, 2015. Saint Petersburg. Name of sections and disciplines: Stages of drug development; Health technology assessment (HTA): history, goals, and the basic principles; Models and approaches for HTA; Effectiveness and efficacy of health technologies. Comparative studies; Adverse events; Basics of clinical and economic analysis. Pharmacoeconomics; Analysis of the results. Working with literature. Medical statistics; Reporting and publishing of the results; Development, adoption and evaluation of management decisions; Using HTA to justify the selection of therapy - some legal issues.

Please indicate who prepared this report, include title, phone, email.

Professor Alexey Kolbin, MD, PhD, Doctor of Science Head of the department of clinical pharmacology and evidence-based medicine  First Pavlov State Medical University of St. Peterburg  Professor of Department of Pharmacology, Faculty of Medicine St. Petersburg State University  197022, Russia, St. Petersburg, Lva Tolstogo 6-8  Tel: 89217590449 mail: alex.kolbin@mail.ru